Pharmaceutical stocks continued their strong upward momentum with Lupin and Torrent Pharmaceuticals hitting new highs, while Sun Pharmaceutical Industries quoted close to its record high. According to reports from Business Standard, these three stocks gained up to 2% on the BSE in Wednesday's intra-day deals. The broader pharma sector significantly outperformed the overall market, with Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences, Senores Pharmaceuticals and Acutaas Chemicals from the BSE Healthcare index rallying between 3% and 13%. In comparison, the Nifty 50 and BSE Sensex were down 0.5% and 0.6% respectively, highlighting the sector's strong performance amid market weakness.
Choice Institutional Equities expects its coverage universe to deliver another quarter of healthy growth in the April to June 2026 quarter (Q1FY27). As reported by Business Standard, growth is anticipated to be supported by continued scale-up of recent product launches, resilient demand in domestic chronic therapies and sustained momentum across emerging markets. However, margin performance is likely to remain mixed in the near term due to pricing pressure and higher investment spending to support new launches and strategic acquisitions. Analysts view these headwinds as largely transitory, as companies continue to invest in higher-margin speciality, biosimilar, peptide and complex product portfolios.
Following the initial surge in industry optimism for Semaglutide, demand growth has begun to normalise towards a more sustainable trajectory. According to Business Standard, the competition landscape has narrowed down, with only a handful of companies including Sun Pharma and Dr Reddy's appearing well-positioned to capture a meaningful market share. While the long-term glucagon-like peptide-1 (GLP-1) opportunity remains compelling, analysts believe near-term performance will increasingly be determined by execution capability, launch scale-up and market penetration rather than the size of the addressable market alone.
Despite near-term headwinds, brokerage firms maintain a positive outlook on the sector, supported by a robust pipeline of launches, an ongoing shift toward complex generics and sustained growth in Biosimilars and Contract Development and Manufacturing Organization (CDMO) segments. As reported by YES Securities, domestic pharma businesses would be in focus for Semaglutide ramp-up amidst emerging concerns of slow off-take. The brokerage expects Sun and Dr Reddy's to report strong India momentum while Lupin Q1 US might represent a gradual climb down from a strong FY26 performance.
